(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 49.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Adc Therapeutics Sa's revenue in 2026 is $81,357,000.On average, 8 Wall Street analysts forecast ADCT's revenue for 2026 to be $10,008,173,233, with the lowest ADCT revenue forecast at $8,828,058,210, and the highest ADCT revenue forecast at $11,728,861,990. On average, 7 Wall Street analysts forecast ADCT's revenue for 2027 to be $16,842,270,275, with the lowest ADCT revenue forecast at $14,592,314,730, and the highest ADCT revenue forecast at $18,755,558,276.
In 2028, ADCT is forecast to generate $37,107,115,500 in revenue, with the lowest revenue forecast at $28,014,550,942 and the highest revenue forecast at $49,890,318,601.